Survival impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in head and neck cancer.

Survival impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in head and neck cancer.
复制标题

DOI:
10.1002/hed.26809
复制
发表时间:
2021-11
期刊:
Head & neck
影响因子:
--
通讯作者:
Karam SD
Karam SD
中科院分区:
其他
文献类型:
--
作者:
Stokes WA;Molina E;McDermott JD;Morgan RL;Bickett T;Fakhoury KR;Amini A;Karam SD

文献摘要

参考文献

被引文献

相似文献

临床前证据表明,肾素-血管紧张素系统与肿瘤发生之间存在联系。我们旨在探讨血管紧张素转换酶抑制剂(ACEI)和血管紧张素II受体阻滞剂(ARB)在头颈癌(HNC)中的作用。从监测、流行病学和最终结果-医疗保险关联数据集确定了超过5,000名患者,并根据ACEI和ARB以及慢性肾脏疾病(CKD)或高血压(HTN)的诊断进行分类。总生存率(OS)和肿瘤特异性生存率(CS)的比较采用COX多变量回归(MVA),以风险比(HR)表示,95%可信区间(95%CI)。未发现与ACEI的OS或CS显著相关的MVA。与服用ARB的CKD/HTN患者相比,未服用ARB的CKD/HTN患者的OS(HR 1.28,95%CI 1.09~1.51,p=0.003)和CS(HR 1.23,95%CI 1.00~1.50,p=0.050)更差。慢性肾脏病或高血压性肾炎HNC患者ARB的使用与OS和CS的改善有关。
Preclinical evidence suggests a link between the renin-angiotensin system and oncogenesis. We aimed to explore the impact of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) in head and neck cancer (HNC). Over 5,000 patients were identified from the Surveillance, Epidemiology, and End Results-Medicare linked dataset and categorized according to ACEi and ARB and diagnoses of chronic kidney disease (CKD) or hypertension (HTN). Overall survival (OS) and cancer-specific survival (CSS) were compared using Cox multivariable regression (MVA), expressed as hazard ratios (HR) with 95% confidence intervals (95%CI). No significant MVA associations for OS or CSS were found for ACEi. Compared to patients with CKD/HTN taking ARB, those with CKD/HTN not taking ARB experienced worse OS (HR 1.28, 95%CI 1.09–1.51, p=0.003) and CSS (HR 1.23, 95% 1.00–1.50, p=0.050). ARB usage is associated with improved OS and CSS among HNC patients with CKD or HTN.
DOI: 10.1007/s12094-016-1608-8
发表时间: 2017-07-01
影响因子: 3.4
作者:
Kim, S. -A.;Moon, H.;Kim, S. Y.
通讯作者: Kim, S. Y.
DOI: 10.2147/tcrm.s165531
发表时间: 2018
影响因子: 2.8
作者:
Liu JQ;Cai GY;Wang SY;Song YH;Xia YY;Liang S;Wang WL;Nie SS;Feng Z;Chen XM
通讯作者: Chen XM
DOI: 10.1007/s00432-004-0582-7
发表时间: 2004-10-01
影响因子: 3.6
作者:
Yasumatsu, R;Nakashima, T;Komune, S
通讯作者: Komune, S
DOI: 10.1093/carcin/bgh324
发表时间: 2005-02-01
期刊: CARCINOGENESIS
影响因子: 4.7
作者:
Fujita, M;Hayashi, I;Majima, M
通讯作者: Majima, M
DOI: 10.1016/s0895-4356(00)00256-0
发表时间: 2000-12-01
影响因子: 7.2
作者:
Klabunde, CN;Potosky, AL;Warren, JL
通讯作者: Warren, JL